Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zimmer Biomet Holdings, Inc. (NYSE: ZBH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zimmer Biomet is a global medical technology company focused on musculoskeletal health and orthopedic implants, and its filings offer detailed insight into its operations, capital structure, risk factors and governance.
Through this page, you can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss Zimmer Biomet’s product categories such as knees, hips, sports medicine, extremities, trauma, craniomaxillofacial and thoracic (S.E.T.), and technology and data, bone cement and surgical. These reports typically include segment and geographic sales information, descriptions of the company’s digital and robotic technologies, and management’s discussion and analysis.
You will also find current reports on Form 8-K covering material events, including quarterly earnings releases, new debt issuances, revolving credit agreements, acquisitions such as the merger with Monogram Technologies Inc., and other significant corporate developments. Filings describing the company’s notes and bonds, including series listed on the New York Stock Exchange, provide detail on interest rates, maturities, covenants and redemption features.
Stock Titan enhances these documents with AI-powered summaries that explain key points in clear language, helping users navigate complex topics like non-GAAP financial measures, leverage covenants and transaction structures. The platform also surfaces insider and executive-related filings, such as those reporting departures or appointments of certain officers, so users can track governance changes. With real-time updates from EDGAR and AI-generated highlights, this page is a focused resource for analyzing Zimmer Biomet’s SEC reporting history and ongoing regulatory disclosures.
Zimmer Biomet Holdings executive Yi Sang reported equity awards and conversions, increasing his direct holdings through stock-based compensation. He acquired 2,382 shares of common stock on
On the same date, he also acquired 2,382 RSUs through an exercise or conversion and received a new grant of 9,043 RSUs. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock and vests annually over three years in one-third increments starting on
Zimmer Biomet Holdings, Inc. executive Wilfred Van Zuilen, Group President EMEA, reported equity-based compensation activity. He exercised 2,451 restricted stock units (RSUs) into the same number of common shares at a stated price of $0.00 per share, increasing his directly held common stock to 24,093 shares before tax withholding. As part of this event, the company granted him an additional 10,334 RSUs, each representing a contingent right to receive one share of common stock, vesting annually over three years in one-third increments starting on February 20, 2027. To cover tax obligations on the RSU vesting, 638 common shares were withheld by the company at $98.62 per share, leaving him with 23,455 directly owned common shares, which include 169 shares acquired earlier under the Employee Stock Purchase Plan.
Zimmer Biomet Holdings, Inc. senior vice president and chief human resources officer Lori Winkler reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 20, 2026, 1,845 RSUs were converted into 1,845 shares of common stock, and she received a new grant of 7,880 RSUs. According to the disclosure, each RSU represents a contingent right to receive one share of company common stock, and the new grant vests annually over three years in one-third increments starting February 20, 2027. The filing also shows 683 shares of common stock were withheld by the company at $98.62 per share to satisfy tax withholding obligations related to the RSU vesting.
Zimmer Biomet Holdings, Inc. reported that VP, Controller and Chief Accounting Officer Paul A. Stellato received new equity awards and related share movements. On February 20, 2026, he acquired 701 restricted stock units (RSUs) through an exercise or conversion and received additional RSU grants of 2,842 and 4,651 units at no cost. Each RSU represents a contingent right to one share of common stock, with one grant vesting annually over three years starting February 20, 2027, and the other vesting in full on February 20, 2028.
The 701 RSUs were converted into 701 shares of common stock, increasing his direct common stock holdings before tax withholding. To cover tax obligations on the RSU vesting, 362 common shares were withheld by the company at a price of $98.62 per share, leaving him with 4,109 common shares directly held, which includes 60 shares previously acquired under the Employee Stock Purchase Plan.
Zimmer Biomet Holdings, Inc. Chairman, President and CEO Ivan Tornos reported equity award and related share movements. He acquired 15,996 shares of common stock through the exercise of restricted stock units and received a new grant of 65,103 restricted stock units, each representing one future share of common stock.
To cover tax withholding on the RSU vesting, 8,846 common shares were withheld by the company at a price of $98.62 per share, a tax-withholding disposition rather than an open-market sale. After these transactions, Tornos directly owned 59,149 shares of common stock, which include 246 shares acquired under the Employee Stock Purchase Plan, and 65,103 restricted stock units that vest in three equal annual installments starting February 20, 2027.
Zimmer Biomet Holdings, Inc. executive vice president and CFO Suketu Upadhyay reported equity compensation activity involving restricted stock units (RSUs) and common stock. He received a grant of 21,701 RSUs, each representing a contingent right to one share of Zimmer Biomet common stock, vesting annually over three years in one-third increments starting February 20, 2027.
On the same date, 5,445 RSUs were converted into 5,445 shares of common stock through an exercise or conversion transaction. Of those shares, 2,446 were withheld by the company at a price of $98.62 per share to satisfy tax withholding obligations tied to the RSU vesting. Following these transactions, Upadhyay directly owned 57,753 shares of common stock.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported an equity compensation award tied to past performance. She acquired 3,935 performance-based restricted stock units, each representing one share of common stock, following a determination on February 19, 2026 of results for the 2023–2025 performance period. These 3,935 RSUs will vest on March 6, 2026, subject to the award’s terms.
Zimmer Biomet Holdings reported that Group President, EMEA, Wilfred Van Zuilen acquired 4,843 restricted stock units (RSUs) as an equity award. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock. These RSUs were earned based on performance for the 2023–2025 period, as determined on February 19, 2026, and are scheduled to vest on March 6, 2026.
ZIMMER BIOMET HOLDINGS, INC. executive vice president and CFO Suketu Upadhyay reported an acquisition of 10,217 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of company common stock at no purchase price.
The RSUs were originally granted as performance-based awards on March 6, 2023, with results tied to a performance period covering 2023 to 2025. Based on actual performance determined on February 19, 2026, 10,217 RSUs were earned and are scheduled to vest on March 6, 2026, if vesting conditions are satisfied.
ZIMMER BIOMET HOLDINGS, INC. reported that executive Paul A. Stellato, its VP, Controller and Chief Accounting Officer, acquired 1,363 restricted stock units as part of a performance-based equity award. These RSUs were earned based on performance for the 2023–2025 period and are scheduled to vest on March 6, 2026.